114 related articles for article (PubMed ID: 34938297)
1. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
2. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
4. A theoretical study on the activity and selectivity of IDO/TDO inhibitors.
Wujieti B; Feng X; Liu E; Li D; Hao M; Zhou L; Cui W
Phys Chem Chem Phys; 2024 Jun; 26(23):16747-16764. PubMed ID: 38818624
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cancer-specific immune responses by amino acid degrading enzymes.
Timosenko E; Hadjinicolaou AV; Cerundolo V
Immunotherapy; 2017 Jan; 9(1):83-97. PubMed ID: 28000524
[TBL] [Abstract][Full Text] [Related]
6. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumours and their microenvironment.
de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
[TBL] [Abstract][Full Text] [Related]
8. X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Ning XL; Li YZ; Huo C; Deng J; Gao C; Zhu KR; Wang M; Wu YX; Yu JL; Ren YL; Luo ZY; Li G; Chen Y; Wang SY; Peng C; Yang LL; Wang ZY; Wu Y; Qian S; Li GB
J Med Chem; 2021 Jun; 64(12):8303-8332. PubMed ID: 34110158
[TBL] [Abstract][Full Text] [Related]
9. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract][Full Text] [Related]
10. Targeting Dietary and Microbial Tryptophan-Indole Metabolism as Therapeutic Approaches to Colon Cancer.
Wyatt M; Greathouse KL
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33916690
[TBL] [Abstract][Full Text] [Related]
11. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Awuah SG; Zheng YR; Bruno PM; Hemann MT; Lippard SJ
J Am Chem Soc; 2015 Dec; 137(47):14854-7. PubMed ID: 26561720
[TBL] [Abstract][Full Text] [Related]
12. Oxidation of an indole substrate by porphyrin iron(iii) superoxide: relevance to indoleamine and tryptophan 2,3-dioxygenases.
Sacramento JJD; Goldberg DP
Chem Commun (Camb); 2020 Mar; 56(20):3089-3092. PubMed ID: 32052805
[TBL] [Abstract][Full Text] [Related]
13. Angucyclinones with IDO and TDO inhibitory activities isolated from the actinomycetes Umezawaea beigongshangensis.
Cao PR; Ren X; Lin J; Mu YL; Shan YQ; Zhu JT; Xu RY; Zhang XX; Hu WG; Lu XH
Fitoterapia; 2024 Jan; 172():105716. PubMed ID: 37926399
[TBL] [Abstract][Full Text] [Related]
14. Immune-suppressive properties of the tumor microenvironment.
Becker JC; Andersen MH; Schrama D; Thor Straten P
Cancer Immunol Immunother; 2013 Jul; 62(7):1137-48. PubMed ID: 23666510
[TBL] [Abstract][Full Text] [Related]
15. A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.
Krähenbühl L; Goldinger SM; Mangana J; Kerl K; Chevolet I; Brochez L; Horak C; Levesque M; Dummer R; Cheng PF
Neoplasia; 2018 Feb; 20(2):218-225. PubMed ID: 29331888
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of formation of N-formylkynurenine by heme dioxygenases.
Basran J; Efimov I; Chauhan N; Thackray SJ; Krupa JL; Eaton G; Griffith GA; Mowat CG; Handa S; Raven EL
J Am Chem Soc; 2011 Oct; 133(40):16251-7. PubMed ID: 21892828
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Targeting key cellular signaling network for cancer chemotherapy and immunotherapy.
Chi H; Jiang L; Zhang S; Liu Y; Yang G; Tian G
Front Immunol; 2024; 15():1425261. PubMed ID: 38817609
[No Abstract] [Full Text] [Related]
18. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.
Bergholz JS; Wang Q; Kabraji S; Zhao JJ
Clin Cancer Res; 2020 Nov; 26(21):5557-5566. PubMed ID: 32576627
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Targeting key cellular signaling network for cancer chemotherapy and immunotherapy.
Li W; Wang X; Wan D; Li J; Jin Z
Front Immunol; 2024; 15():1423917. PubMed ID: 38803491
[No Abstract] [Full Text] [Related]
20. Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue.
Lambertini M; Marrocco C; Spinaci S; Demeestere I; Anderson RA
Eur J Clin Invest; 2022 Jul; 52(7):e13779. PubMed ID: 35342940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
